Regardless of your pharmacy practice area, you have likely heard the terms specialty pharmacy and specialty pharmaceuticals. With a rich drug pipeline and innovative programs like specialty-at-retail, specialty pharmacy permeates many areas of the industry. So what exactly do those two terms mean? Although this question is often asked, one accepted, industry-wide definition for either term remains elusive.
In defining a specialty pharmaceutical, there are two main factors: cost and complexity. Using a cost-based approach, CMS categorizes a specialty drug as one with a minimum monthly cost of $600 with respect to the Part D drug benefit. Other organizations utilize a higher cost threshold for specialty classification that may be as much as double that of CMS. Complexity can encompass a number of factors and affect various groups, including patients, payers, manufacturers, and the pharmacy itself.
A medication considered a specialty pharmaceutical may have some or all of the following key characteristics:
Although this category has historically focused on injectable and infused formulations, a significant number of specialty medications in oral dosage forms have entered the market recently. This trend is only expected to continue, especially among oral oncolytics. Due to the complexities associated with specialty pharmaceuticals, patients receiving these medications require a significant degree of continuous patient education, ongoing monitoring, and medication management by well-qualified and skilled specialty pharmacy staff.
The Academy of Managed Care Pharmacy, in its Format for Formulary Submissions, and the Specialty Pharmacy Association of America both recently published definitions of specialty pharmacy. Commonalities seen within the definitions include the distribution of specialty pharmaceuticals and high-touch, patient-centered management that maximally benefits the patient’s medication experience. Ideally, this translates into improved care with measurable, positive clinical outcomes.
As part of this patient-focused model, specialty pharmacies offer services above and beyond those typically offered at the retail level as part of their standard of care. These may include the following:
Common disease states managed by specialty pharmacies include oncology, multiple sclerosis, rheumatoid arthritis, Crohn disease, HIV/AIDS, hepatitis C, and growth hormone disorders, among others.
Specialty pharmacy, which once occupied only a small niche in the marketplace, has become a burgeoning industry. Pharmacists, regardless of their area of practice, should understand the place of specialty pharmacy within the industry, even though the field may be difficult to define. Collaborations between specialty pharmacies, retail settings, hospitals, and manufacturers are becoming increasingly commonplace. These collaborations can enhance patient access to specialty pharmaceuticals and the high-touch services a specialty pharmacy can provide, thereby improving patient care.